Evaluation of Right Ventricular and Left Ventricular Function in Patients with Chronic Obstructive Pulmonary Disease by TDI Index

  • Ni Wang
Keywords: TDI index; Chronic obstructive pulmonary disease; Right ventricle; Left ventricle


Dyspnea is the main symptom of chronic obstructive pulmonary disease (KD), so in addition to lung function, assessing treatment outcome is also a valuable outcome. To more fully assess the impact of TDI index on right ventricular and left ventricular function in patients with chronic obstructive pulmonary disease, four 1-year studies were performed. In this pooled analysis, roflumilast significantly improved the TDI index at week 52 (treatment difference, 0.327; P < 0.01). Compared with placebo, roflumilast was associated with a significantly greater TDI index and significantly fewer TDI exacerbations (increased or decreased by ≥1 unit from baseline) at week 52 (P<0.01, both There are); these significant differences appeared in the 8th week and continued until the end of the study (P < 0.05, all). At the end of the study, roflumilast had a significant increase in forced expiratory volume after bronchiectasis in 1 second compared with placebo (P < 0.05). Similar to the overall population, patients with chronic bronchitis had a slightly improved TDI lesion score at week 52, but continued to be significantly higher than placebo, regardless of whether they had a worsening history, concurrent use of short-acting muscarinic antagonists or long-acting beta 2 agonism. This analysis suggests that patients receiving roflumilast therapy to reduce the risk of exacerbation may have a slight but significant improvement in dyspnea with an improvement in lung function.